Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.61 |
| ▸ | TLR2 | O60603 | 1/20 | 0.61 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.61 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15618978 | 0.84 | ERN1 (0.53) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL4628099 | 0.83 | LMNA (0.48) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL17023571 | 0.80 | ERN1 (0.49) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL9091710 | 0.80 | CYP19A1 (0.44) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL5047419 | 0.79 | ERN1 (0.51) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL27537103 | 0.79 | ALDH1A1 (0.48) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL738533 | 0.79 | ERN1 (0.66) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL30203585 | 0.79 | ERN1 (0.66) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL29954368 | 0.79 | ERN1 (0.66) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL21834684 | 0.79 | TLR2 (0.51) | ERN1TLR2TLR1TLR6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4686366-A1 | THE USE OF QUINOLIN-8-OLATE DERIVATIVES AND A DEVICE COMPRISING THE SAME | Noctiluca S.A. (PL) | 2026-01-28 | — | — | EP | disclosed |
| US-20240092802-A1 | MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR | KURES, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2023161844-A1 | USE OF HPK1 INHIBITOR IN TREATMENT OF INTERFERON-RELATED DISEASES | 智宠制药（北京）有限公司 | 2023-08-31 | — | — | WO | disclosed |
| CN-113620875-B | 3-nitrile quinoline derivative and preparation method thereof | 郑州大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-110746396-B | Selenium-containing isoxazolidine compound and preparation method and application thereof | 上海星叶医药科技有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3116509-B1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | UNIV COLUMBIA (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3116509-B1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | UNIV COLUMBIA (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022074587-A1 | MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-04-07 | — | — | US | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6617336-B1 | Treatment of urinary incontinence, venous insufficiency, migraine or gastrointestinal disorders | SANOFI-SYNTHELABO (FR) | 2003-09-09 | — | — | US | disclosed |
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | BAXTER ONCOLOGY GMBH | 2003-08-21 | — | — | US | disclosed |
| US-20030097000-A1 | 2-Phenyl-quinoline derivatives, preparation method and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2003-05-22 | — | — | US | disclosed |
| EP-1242381-A2 | 2-PHENYL-QUINOLINE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-09-25 | — | — | EP | disclosed |
| EP-1240146-A1 | 2-ARYLQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044197-A2 | 2-PHENYL-QUINOLINE DERIVATIVES AND THEIR USE AS CONTRACTING AGENT FOR SMOOTH MUSCLES | SANOFI-SYNTHELABO (FR) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001038310-A1 | 2-ARYLQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092802-A1 | MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR | OPRL1, OPRM1, CDKL5 | ERN1 2608/4885TLR2 4043/4885TLR1 2397/4885 |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ERN1 4880/4885TLR2 237/4885TLR1 441/4885 |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | OPRM1, OPRL1, OPRK1 | ERN1 2606/4885TLR2 668/4885TLR1 374/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ERN1 4880/4885TLR2 237/4885TLR1 441/4885 |
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | ERN1 3927/4885TLR2 3564/4885TLR1 4302/4885 |
| US-20030097000-A1 | 2-Phenyl-quinoline derivatives, preparation method and therapeutic use thereof | CYP2F1, CYP4F2, CYP4F3 | ERN1 3124/4885TLR2 2311/4885TLR1 2014/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ERN1 4874/4885TLR2 164/4885TLR1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.